NYU Langone's Perlmutter Cancer Center | Strategic Alliance Partners

March 28, 2020

Scott T. Tagawa, MD, MS, discusses remaining questions regarding treatment selection and PSMA imaging in metastatic castration-resistant prostate cancer.

March 25, 2020

Mohammad Maher Abdul Hay, MD, discusses the process of evaluating the eligibility of patients with acute lymphoblastic leukemia for transplant.

March 25, 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses the use of ruxolitinib (Jakafi) in the treatment of patients with myeloproliferative neoplasms.

March 24, 2020

Michael L. Grossbard, MD, discusses the role of minimal residual disease in follicular lymphoma.

March 23, 2020

David Polsky, MD, PhD, discusses the use of circulating tumor DNA (ctDNA) in the COMBI-d trial on melanoma.

March 20, 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses the role of transplant in myeloproliferative neoplasms.

March 19, 2020

Shella Saint Fleur-Lominy, MD, PhD, an assistant professor in the Department of Medicine at NYU Langone Health

March 18, 2020

Mohammad Maher Abdul Hay, MD, discusses the evolving role of transplant in acute lymphoblastic leukemia.

March 17, 2020

Mohammad Maher Abdul-Hay, MD, an assistant professor in the Department of Medicine; director of the Clinical Leukemia Program in NYU Langone Health’s Perlmutter Cancer Center; and associate director for research in the Bellevue Cancer Center, discusses treatment considerations in acute lymphoblastic leukemia (ALL).

March 17, 2020

Michael L. Grossbard, MD, professor in the Department of Medicine, chief of the Hematology and Medical Oncology Inpatient Service at Tisch Hospital, and section chief of Hematology at NYU Langone Health’s Perlmutter Cancer Center, discusses the results of the phase III GALLIUM study in follicular lymphoma.

March 16, 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses the differences between ruxolitinib and fedratinib in the treatment of patients with myeloproliferative neoplasms.

March 12, 2020

Several faculty who were on site at the 2020 Miami Breast Cancer Conference touch upon COVID-19.

March 11, 2020

Mohammad Maher Abdul-Hay, MD, an assistant professor in the Department of Medicine; director of the Clinical Leukemia Program in NYU Langone Health’s Perlmutter Cancer Center; and associate director for research in the Bellevue Cancer Center, discusses the use of bispecific T-cell engagers (BiTEs) in acute lymphoblastic leukemia (ALL).

March 10, 2020

David Polsky, MD, PhD, discusses the unmet need of clinical utility in liquid biopsy.

March 10, 2020

Bruce G. Raphael, MD, a clinical professor in the Department of Medicine at NYU Langone Health, discusses the phase II CLARITY trial in chronic lymphocytic leukemia (CLL).

March 09, 2020

Mohammad Maher Abdul-Hay, MD, discusses current standards for the treatment of patients with acute lymphocytic leukemia.

March 09, 2020

Gareth J. Morgan, MD, PhD, discusses ongoing research of BCMA-targeted therapies, as well as the use of venetoclax in the myeloma treatment paradigm.

March 07, 2020

Gareth J. Morgan, MD, PhD, discusses ongoing research of BCMA-targeted therapies, as well as the use of venetoclax in the myeloma treatment paradigm.

March 06, 2020

Bruce G. Raphael, MD, discusses recent pivotal trials in chronic lymphocytic leukemia and the utility of triplet regimens for older patients.

March 06, 2020

Marc J. Braunstein, MD, PhD, expands on the 3- and 4-drug regimens that are showing promise in the multiple myeloma paradigm.